



## Breadcrumb

1. [Home](#)

## Entity Print



Bertram Glass  
LWP Chair  
Germany

## Major achievements

The most important piece of work of the LWP is to assess the impact of CART treatment on the therapeutic landscape of lymphoma. We formulated a proposal to the GoCART-consortium named TRANSCART. In this project the outcome of anti-CD19 CARTs in their current indication (third-line treatment of DLBCL and

PMBCL) and allogeneic SCT will be described and compared. After definitions parameters and endpoints, the feasibility analysis revealed that more than 400 patients with each treatment modality can be included analysis. The project was selected by GoCART as one of three scientific projects to be promoted within the first call.

A combined EBMT / CIBMTR analysis: “Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics” was completed and published in Blood advances. In two additional projects regarding the outcome of allogeneic SCT in Hodgkin’s lymphoma in the era of checkpoint inhibitors and the comparison of ATG and PT-CY in lymphoma patients and MMUD, the analysis has been completed and abstracts have been sent in for the next EBMT meeting.

A new prospective register study on the use of Brentuximab vedotin in the context of autologous SCT in HL has been successfully get sponsoring from a pharmaceutical company and will be launched early in 2022.

The educational course of the LWP as a face to face meeting has been successfully been held from October 21-22 in Münster, Germany.

Currently additional 6 projects have successfully passed the feasibility analysis and have been approved by the LWP.

## **Principal research studies**

[Allogeneic Stem Cell TransplantationIn NK/ T-cell lymphoma](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

-

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Norbert Schmitz](#)

[Non-Interventional Study on the use of Brentuximab Vedotin or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma](#)

[Study type](#)

[Non-interventional Prospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Ali Bazarbachi](#)

[Outcomes of Allogeneic HCT in patients with Hodgkin Lymphoma in the era of Checkpoint Inhibitors: A joint CIBMTR and EBMT analysis.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Hodgkin's Disease \(HD\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Miguel-Angel Perales](#)

[Real life analysis BV use as consolidation therapy in HL with high risk post ASCT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Hodgkin's Disease \(HD\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Mariana Bastos Oreiro](#)

## **Key publications**

[2021](#)

[Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics](#)

Group

Lymphoma Working Party (LWP)

1st listed author

Mehdi Hamadani

Journal

Blood Adv.

2021

Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT

Group

Lymphoma Working Party (LWP)

1st listed author

G Gutiérrez-García

Journal

Br J Haematol.

2021

Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

Group

Lymphoma Working Party (LWP)

1st listed author

Toby A Eyre

Journal

Bone Marrow Transplant.

2021

Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Group

Lymphoma Working Party (LWP)

1st listed author

E Domingo-Domenech

Journal

Bone Marrow Transplant.

2021

[Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[R Pettengell](#)


[Journal](#)

[Bone Marrow Transplant.](#)

[See the full list of the LWP 2021 publications](#)



Impact factor  
(Lymphoma)



**2019 2020 2021**

<b>Oral presentations</b>	7	1	<b>1</b>
<b>Poster presentations</b>	4	0	<b>0</b>
<b>Educational events</b>	1	1	<b>1</b>



[Event](#)

## [\*\*Lymphoma Working Party Educational Course\*\*](#)

[Oct 21, 2021 - Oct 22, 2021 / Münster, Germany](#)

[Discover more](#)